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Given the potential for laboratory-associated severe
acute respiratory syndrome–associated coronavirus
(SARS-CoV) infections, we must know which cell lines are
susceptible to the virus. We investigated 21 cell lines rou-
tinely used for virus isolation or research. After infection with
SARS-CoV, cells were observed for cytopathic effects, and
quantitative real-time polymerase chain reaction was used
to measure ongoing viral replication. An indirect immunoflu-
orescence assay was also used as a confirmatory test. The
study identified 10 new cell lines capable of supporting the
replication of SARS-CoV and confirmed the susceptibility of
4 cell lines previously reported. This study shows that
SARS-CoV can be isolated in several cell lines commonly
used for diagnostic or research purposes. It also shows that
SARS-CoV can achieve high titers in several cell lines,
sometimes in the absence of specific cytopathic effects.
S
evere acute respiratory syndrome (SARS) was first
observed in 2002 when cases of a life-threatening atyp-
ical pneumonia occurred in Guangdong Province, China
(1). A novel coronavirus (CoV), designated SARS-CoV,
was quickly identified as the etiologic agent (1,2).
Although the origins of the virus have not been estab-
lished, evidence suggests that it is an animal virus that was
recently transmitted to humans (3). Several wildlife
species consumed as delicacies in southern China, includ-
ing Himalayan masked palm civets, Chinese ferret badg-
ers, and raccoon dogs, possess antibodies consistent with
natural infection with related CoVs (4).
Unlike the other currently recognized human CoVs,
HCoV-229E, HCoV-OC43, HCoV-NL63, and HKU1,
which usually cause mild upper respiratory tract infections
and occasionally pneumonia in older adults, neonates, and
immunocompromised patients (5–8), SARS-CoV causes
severe febrile lower respiratory tract illness that leads to
pneumonia and acute respiratory distress (9,10). Death
from progressive respiratory failure due to alveolar dam-
age occurs in ≈10% of patients with symptomatic infection
(2,10). Currently the world is free of SARS, but we cannot
predict whether the virus will reemerge. The most proba-
ble sources of future infections are exposure to animal
reservoirs or laboratories where SARS-CoV is manipulat-
ed for research purposes. Indeed, since the first epidemic,
SARS has occurred on 3 occasions as a result of breaches
in laboratory biosafety procedures (11–13). This finding
highlights the importance of safely handling SARS-CoV,
especially in diagnostic virology laboratories where virus
isolation is performed and in research laboratories where
infectious virus is handled.
SARS-CoV was first isolated in Vero E6 and FRhK
cells injected with clinical specimens as part of early
attempts to identify the etiologic agent of SARS (10,14).
Simultaneously, these investigations showed that SARS-
CoV could not replicate in a number of other cell lines rou-
tinely used for respiratory virus isolation. More recently,
additional human and animal cell lines that support SARS-
CoV replication have been identified (15). Given the
potential for SARS-CoV infection to occur in a laboratory
setting, we must be aware of cell lines in which it can repli-
cate. Therefore, we investigated the susceptibility of a
number of cell lines to SARS-CoV. These cells were
derived from a variety of species and tissues and included




An isolate of SARS-CoV, strain HKU 39849, was pas-
saged on 2 occasions in Vero E6 cells to establish a high-
titer stock that was used in all infectivity experiments.
Because SARS-CoV is classified as a risk group level 4
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Melbourne, Victoria, Australiapathogen in Australia, all procedures performed with the
virus, including infecting cell lines and viral lysis before
RNA extraction, were carried out in a physical contain-
ment level 4 (PC4) laboratory.
Cell Lines
The cell lines investigated for their susceptibility to
SARS-CoV are shown in the Table. They were chosen
because they were present in our cell repository and were
used either routinely or occasionally for virus isolation
attempts as part of diagnostic or research projects.
Confluent cells were maintained at 34°C in 25-mL flasks
(Nunc, Roskilde, Denmark) containing 10 mL appropriate
maintenance medium supplemented with fetal bovine
serum (FBS) (Thermo Trace, Melbourne, Victoria,
Australia), 100 U/mL penicillin, and 100 µg/mL strepto-
mycin (JRH Biosciences, Lenexa, KS, USA). BGM,
FRhK, HEK-293, HEL, Hep G2, L20, MA-104, pCMK,
and RD-Acell lines were all maintained in modified Eagle
medium (MEM) supplemented with 10% FBS. MDCK
cells were maintained in MEM supplemented with 5%
FBS. HeLa-T cells were maintained in basal medium
Eagle supplemented with 10% FBS. COS, Huh-7, Vero,
and Vero E6 cell lines were maintained in Dulbecco mod-
ified Eagle medium (DMEM) supplemented with 10%
FBS. CV-1, Hep-2, LLC-Mk2, MEK, and RK-13 cells
were maintained in 199 medium with 5% FBS, and A549
cells were maintained in RPMI 1640 medium supplement-
ed with 10% FBS. Confluent cells were infected with
SARS-CoV, which resulted in a multiplicity of infection of
1.7 (results not shown) or were mock-infected with medi-
um only. An additional flask was also prepared in which
the original inoculum was incubated under the same exper-
imental conditions but within a cell-free environment.
On days 4, 7, and 11 after infection, cells were observed
for SARS-CoV–specific cytopathic effects (CPE), super-
natants were collected for virus detection and quantifica-
tion by polymerase chain reaction (PCR), and the
maintenance medium was replaced. Cells were tested for
virus-specific antigens with an indirect immunofluores-
cence assay 11 days after infection with SARS-CoV if no
CPE was observed (or when CPE developed that involved
at least 75% of the cell monolayer). Eleven days after
infection, cell lines negative for indicators of viral replica-
tion were blind-passaged twice for 7 days by adding
100 µL culture supernatant to the cells in question as well
as to the highly susceptible Vero E6 cells. During these
passages, cells were observed for SARS-CoV–specific
CPE, and after the second passage, supernatants were col-
lected for virus detection and quantification by PCR.
RNA Extraction
A 300-µL volume of lysis buffer containing guanidini-
um thiocyanate and Triton X-100 (Roche Diagnostics,
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from cell cultures that had either been infected with SARS-
CoV or were mock-infected. These samples were removed
from the PC4 laboratory to a PC2 laboratory, where they
underwent nucleic acid extraction with a MagNA Pure LC
Total Nucleic Acid Isolation Kit with a MagNA Pure LC
automated extraction robot (Roche Diagnostics). A 10-µL
volume of eluate was treated for 10 min at 65°C and added
to 12 mL reverse transcription master mix containing 5.2
A260 U/mL random hexamers (Roche Diagnostics),
0.17 µmol/L deoxynucleoside triphosphates (Roche Diag-
nostics), and 7.5 U AMV-RT enzyme (Promega, Madison,
WI, USA). After incubation at 42°C for 30 min, then
100°C for 10 min, cDNAproducts were stored at 4°C until
analyzed by PCR.
Quantitative Real-time PCR for SARS-CoV
Real-time PCR that amplified an 81-bp fragment of the
nucleoprotein gene was used to detect and quantify SARS-
CoV by reference to a cycle threshold (Ct). The assay used
ABI-7000 Prism instrumentation (Applied Biosystems,
Foster City, CA, USA) with primers and probes designed
with the associated Primer Express software. The forward
primer was SARNP-F: 5′-CCC AGATGG TAC TTC TAT
TAC CTAGGA-3′. The reverse primer was SARNP-R: 5′-
CCA TAC GAT GCC TTC TTT GTT AG-3′. The probe
was SARNP-P: 6FAM 5′-AAG CTT CAC TTC CCTACG
G-3′ with 3′ MGB. For real-time PCR, 5 µL template
cDNA was added to ABI TaqMan Universal PCR Master
Mix (Applied Biosystems) containing 0.9 µmol/L each
primer and 0.2 µmol/L probe in a total volume of 45 mL.
The cycling conditions were as follows: 2 min at 50°C, 10
min at 95°C, then 45 cycles of 15 s at 95°C and 1 min at
60°C. Reference to a standard curve (not shown) demon-
strated that negative changes in Ct values of 3.6 represent-
ed increases in virus titer of 1.0 log10.
Indirect Immunofluorescence Assay
Cells were collected 11 days after infection if no CPE
was observed by microscopy or on the day they developed
CPE involving at least 75% of the cell monolayer. Cells
were manually scraped from monolayers into 1 mL culture
medium, then subjected to 50 kGy gamma radiation before
being spotted onto a slide, air dried, and fixed in acetone
for 10 min. Earlier testing showed that this dose of gamma
radiation reduced the titer of SARS-CoV by at least 106
50% tissue culture infectious doses (results not shown). A
10-µL volume of diluted convalescent-phase serum from a
SARS-CoV–infected patient was added to the fixed cells
followed by incubation at 37°C for 30 min in a humidified
chamber. The slides were washed twice with phosphate-
buffered saline (PBS), dried, and each cell spot overlaid
with 10 µL anti-human fluorescein isothiocyanate–conju-
gated secondary antibody (BioMérieux, Durham, NC,
USA) for 30 min at 37°C. The slides were washed twice
with PBS before they were mounted with cover slips.
Virus-specific immunofluorescence was read by using an
Axioskop UV microscope (Zeiss, Oberkochen, Germany).
The final results for the indirect immunofluorescence
assay, as shown in the Table, were based on the observa-
tions of 2 independent readers.
Results
Susceptibilities to SARS-CoV of the cell lines we
investigated are shown in the Table. The results obtained
on 21 lines are indicated: 14 were tested for the first time,
and 7 had been previously reported by others (15). Of the
7 cell lines tested previously, we confirmed previous data
that showed that 4 of them could support replication. Of
the 14 lines tested for the first time, 10 were shown to sup-
port replication of SARS-CoV. In general, cells derived
from nonhuman primate kidneys were susceptible. A
human liver cell line (Hep G2) and rabbit kidney cells
(RK-13) also supported replication.
SARS-CoV replication in BGM, CV-1, FRhK, LLC-
Mk2, MA-104, pCMK, RK-13, and Vero cell lines pro-
duced a CPE as early as day 4 after inoculation, with
evidence of high levels of virus-specific RNA established
by quantitative PCR. CPE was focal, with cell rounding
and a refractivity that was soon followed by cell detach-
ment, and CPE quickly spread to involve the entire cell
monolayer (Figure 1). In contrast, neither MEK nor COS
cells produced a SARS-CoV–specific CPE (Figure 1),
despite evidence of rapid (MEK) or limited (COS) replica-
tion, as determined by quantitative PCR (Figure 2) and
indirect immunofluorescence testing (not shown). For the
cell lines capable of supporting SARS-CoV replication,
immunofluorescence results confirmed quantitative PCR
results in all cases (Table).
Figure 2 shows the quantitative PCR results for repre-
sentative cell lines for the 11 days during which isolation
was attempted. The results are depicted as Ct values rela-
tive to the Ct values of a cell-free preparation. The cell-free
preparation had an initial Ct value of 31, obtained when
the original inoculum was seeded into a flask containing
10 mL DMEM. This input Ct increased to a Ct value of 40
by day 11 after infection. The supernatants from BGM,
CV-1, MEK, Vero, and Vero E6 cell lines yielded Ct val-
ues 12–17 units lower than the initial cell-free inoculum by
day 4 after infection. This number equated to titer increas-
es 3.3–4.7 log10/mL above the input virus for these cells.
The results for HeLa-T, Hep-2, and MDCK cells, repre-
senting cell lines that do not support SARS-CoV replica-
tion, are shown in Figure 2. In these cell lines, the Ct
values at 4 days after infection were at levels similar to
those of the cell-free inoculum. At later times, after succes-
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lar to that of the cell-free control preparation, indicating
dilution of input virus and absence of any subsequent viral
replication. Blind passaging of supernatant fluid from
these cell lines confirmed these results (not shown). In
contrast, Ct values for COS cells did not change over the
course of the experiment, which suggests that viral replica-
tion occurred at a low level, sufficient to maintain similar
viral titers to those of input levels through several medium
changes.
Discussion
After the SARS epidemic ended, several cases have
occurred as a direct or indirect result of breaches in labo-
ratory biosafety (11–13). These breaches highlight the
need to safely handle virus in the laboratory, which
includes knowing which cell lines may be susceptible to
infection. In this study we add to the list of cells known to
support replication of SARS-CoV.
Our approach to establishing susceptibility to infection
was to use quantitative PCR supported by immunofluores-
cence testing. The quantitative PCR was used to distin-
guish ongoing viral production from input virus. Other
groups have used alternative strategies to investigate
SARS-CoV replication, including using PCR capable of
amplifying subgenomic RNA molecules produced during
replication (15). Our results show that, in laboratories
where reverse-transcription PCR is not available but
appropriate reagents are available, immunofluorescence
testing is a simple and rapid method of assessing whether
cells exposed to respiratory or enteric specimens are
infected with the virus.
On the basis of this study and earlier reports (10,14,15),
monkey kidney cell lines are particularly susceptible to
SARS-CoV infection. African green, cynomolgus, and
rhesus monkey kidney cell lines have all been previously
shown to be susceptible. We identified for the first time
that kidney cells derived from a fourth nonhuman primate
species, buffalo green monkey, are productively infected
with SARS-CoV, with titers that reach 4.7 log10/mL above
input virus, similar to levels in other monkey kidney cells.
We found most monkey kidney–derived cell lines, includ-
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Figure 1. Cytopathology of uninfected cells (left col-
umn) and the same cells infected in vitro with severe
acute respiratory syndrome–associated coronavirus
(right column). A) Vero cells day 4 after infection.
B) MA-104 cells day 4 after infection. C) Huh-7 cells
day 11 after infection. D) pCMK cells day 11 after
infection. E) COS cells day 11 after infection. F) MEK
cells day 11 after infection.ing BGM, CV-1, FRhK, LLC-Mk2, MA-104, pCMK, and
Vero E6, supported replication of SARS-CoV, with titers
3.9–4.7 log10/mL above input virus titers. High titers of
SARS-CoV attainable in these cell lines should be consid-
ered when using them for virus isolation purposes, and
appropriate safety guidelines should be followed.
The ability of SARS-CoV to replicate efficiently in kid-
ney-derived cell lines is not surprising given that its func-
tional receptor, the metalloprotease angiotensin-converting
enzyme 2 (ACE-2), is highly expressed in kidney tissue
(16). This metalloprotease receptor is widely divergent
from the aminopeptidase N receptor of group 1 CoVs (16)
but is expressed in lung, heart, kidney, and gastrointestinal
tissue, consistent with the pathology of SARS.
Generally, close agreement was seen between our
results and those previously reported (15), although a dif-
ference was seen in CPE. We showed that HEK-293, Huh-
7, and pCMK cells supported development of SARS-
CoV–specific CPE, whereas no CPE was observed in
these cell lines in an earlier study, although replication
occurred (15). In that study, cells were observed for CPE
for only 2 days after infection, whereas in the present
study we observed cells for up to 11 days. In Huh-7 and
pCMK cell lines, we observed that CPE often developed
slowly and affected a population of cells but did not
progress (Figure 1). Neither COS nor MEK cells devel-
oped SARS-CoV–specific CPE (Figure 1), despite evi-
dence of replication by PCR and immunofluorescence.
COS cells are a derivative of the African green monkey
kidney fibroblast cell line CV-1, which is highly suscepti-
ble to SARS-CoV. The reason for the decreased level of
virus production in related COS cells remains to be deter-
mined but may be due to a lower level surface expression
of the ACE-2 receptor. Nevertheless, the results for these
2 cell lines highlight the unreliability of CPE as a measure
of SARS-CoV replication.
Given that primate kidney–derived cell lines are partic-
ularly susceptible to infection with SARS-CoV and virus
has been isolated from the kidney of an infected human
patient (10), we suspect that human kidney–derived cell
lines might also support SARS-CoV replication. However,
until the study by Gillim-Ross et al. (15), no human cell
lines had been shown to be productively infected by
SARS-CoV. We found, in agreement with that study that,
HEK-293 and Huh-7 cells were susceptible to infection
with the virus. In addition, we identified a third human cell
line, Hep G2, derived from a hepatocellular carcinoma,
that was also susceptible to infection, although it produced
lower levels of virus-specific RNA than HEK-293 and
Huh-7 cells. Hep G2 and Huh-7 cell lines are used in
research laboratories to study hepatitis B and C viruses,
which suggests that cell lines used for research purposes
need to be considered carefully for their potential to sup-
port SARS-CoV replication, and guidelines must be estab-
lished to prevent simultaneous work on multiple different
viruses within the same laboratory.
This study has shown that SARS-CoV can be isolated
in several cell lines commonly used for diagnostic and
research purposes and highlights that the virus can achieve
high titers in some cell lines, sometimes in the absence of
CPE. These findings are particularly relevant to laboratory
scientists undertaking virus-isolation procedures on speci-
mens collected from patients with atypical respiratory dis-
ease or in research laboratories where the possibility of
simultaneously handling more than 1 virus exists.
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